Lauren Klein1, Jessica Peters2, James Miner3, Jed Gorlin2. 1. Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN, USA. Electronic address: lauren.klein@hcmed.org. 2. Transfusion Service, Hennepin County Medical Center, Minneapolis, MN, USA. 3. Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN, USA.
Abstract
OBJECTIVES: Four-factor prothrombin complex concentrates (4FPCCs) are emerging as the standard of care for emergent warfarin reversal due to their ability to rapidly and effectively achieve hemostasis. The ideal dose of this medication is not known. Recently, our hospital instituted a protocol where all doses of 4FPCC were a fixed dose of 1500 IU. This protocol provides 4FPCC rapidly and precludes delay waiting for international normalized ratio (INR) values. The purpose of this study was to evaluate our experience with this fixed dose protocol. METHODS: This is a retrospective review of patients who received 1500 IU of 4FPCC for emergent warfarin reversal between March 2014 and January 2015. Demographic and clinical data regarding administration, efficacy, and safety were collected and analyzed. RESULTS: A total of 39 patients met inclusion criteria. The most common indication for treatment was intracranial hemorrhage (28, 71.8%). The median INR at presentation was 3.3, and the median INR after a single dose of 1500 IU was 1.4 (P < .001). A total of 36 patients (92.3%) achieved successful reversal with a target INR of less than 2.0, and 28 patients (71.8%) achieved successful reversal with a target INR of 1.5 or less. There were no thrombotic adverse events within 7 days. CONCLUSIONS: Administration of a fixed dose of 1500 IU of 4FPCC leads to high rates of successful INR reversal and no related thrombotic adverse events within 7 days, and there was no need to wait for INR at presentation. These findings suggest good efficacy and safety when using 1500 IU of 4FPCC for emergent warfarin reversal.
OBJECTIVES: Four-factor prothrombin complex concentrates (4FPCCs) are emerging as the standard of care for emergent warfarin reversal due to their ability to rapidly and effectively achieve hemostasis. The ideal dose of this medication is not known. Recently, our hospital instituted a protocol where all doses of 4FPCC were a fixed dose of 1500 IU. This protocol provides 4FPCC rapidly and precludes delay waiting for international normalized ratio (INR) values. The purpose of this study was to evaluate our experience with this fixed dose protocol. METHODS: This is a retrospective review of patients who received 1500 IU of 4FPCC for emergent warfarin reversal between March 2014 and January 2015. Demographic and clinical data regarding administration, efficacy, and safety were collected and analyzed. RESULTS: A total of 39 patients met inclusion criteria. The most common indication for treatment was intracranial hemorrhage (28, 71.8%). The median INR at presentation was 3.3, and the median INR after a single dose of 1500 IU was 1.4 (P < .001). A total of 36 patients (92.3%) achieved successful reversal with a target INR of less than 2.0, and 28 patients (71.8%) achieved successful reversal with a target INR of 1.5 or less. There were no thrombotic adverse events within 7 days. CONCLUSIONS: Administration of a fixed dose of 1500 IU of 4FPCC leads to high rates of successful INR reversal and no related thrombotic adverse events within 7 days, and there was no need to wait for INR at presentation. These findings suggest good efficacy and safety when using 1500 IU of 4FPCC for emergent warfarin reversal.
Authors: Carmen Sobrino Jiménez; José Antonio Romero-Garrido; Ángeles García-Martín; Manuel Quintana-Díaz; Carlos Jiménez-Vicente; Luis González-Del Valle; Alicia Herrero Ambrosio; Juana Benedí-González Journal: Eur J Hosp Pharm Date: 2020-06-26
Authors: Sarah L Clark; Kimberly Levasseur-Franklin; Mehrnaz Pajoumand; Megan Barra; Michael Armahizer; Deepa V Patel; Katleen Wyatt Chester; Andrea P Tully Journal: Neurocrit Care Date: 2020-02 Impact factor: 3.210
Authors: Jessica Rimsans; Karen Berger; Sarah Culbreth; Christopher Hood; Katleen Chester; Jean M Connors; Laurel Omert Journal: Res Pract Thromb Haemost Date: 2021-11-26